Having trouble accessing articles? Reset your cache.

Cypher: Post-marketing study data

Data from the single-blind, Danish SORT-OUT IV trial in >2,600 patients showed that Cypher was non-inferior to Xience

Read the full 184 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE